On 24 July 2008 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion**, recommending the granting of a marketing authorisation for the medicinal product Olanzapine Mylan 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg film-coated tablets intended for the treatment of schizophrenia. The applicant for this medicinal product is Generics (UK) Ltd.
The active substance of Olanzapine Mylan is olanzapine which is an atypical antipsychotic (N05AH03).
The details can be read here.
No comments:
Post a Comment